Literature DB >> 15014635

Acetylcholinesterase Inhibitors: Treatment of Dementia-Related Behavioral Disturbances.

Sanjay Gupta1, Prakash Masand, Subhdeep Virk.   

Abstract

Entities:  

Year:  2000        PMID： 15014635      PMCID： PMC181147          DOI： 10.4088/pcc.v02n0607

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN： 1523-5998


× No keyword cloud information.
  12 in total

Review 1.  Cholinesterase inhibitors: A new class of psychotropic compounds.

Authors:  J L Cummings
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

Review 2.  Treatment of agitation in dementia.

Authors:  P N Tariot
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

Review 3.  Behavioral disturbances of dementia.

Authors:  B G Pollock; B H Mulsant
Journal:  J Geriatr Psychiatry Neurol       Date:  1998       Impact factor: 2.680

4.  Butyrylcholinesterase in the life cycle of amyloid plaques.

Authors:  A L Guillozet; J F Smiley; D C Mash; M M Mesulam
Journal:  Ann Neurol       Date:  1997-12       Impact factor: 10.422

5.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Authors:  S L Rogers; M R Farlow; R S Doody; R Mohs; L T Friedhoff
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

6.  The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

Authors:  S L Rogers; L T Friedhoff
Journal:  Dementia       Date:  1996 Nov-Dec

7.  Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.

Authors:  N Qizilbash; A Whitehead; J Higgins; G Wilcock; L Schneider; M Farlow
Journal:  JAMA       Date:  1998-11-25       Impact factor: 56.272

8.  A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

Authors:  K L Davis; L J Thal; E R Gamzu; C S Davis; R F Woolson; S I Gracon; D A Drachman; L S Schneider; P J Whitehouse; T M Hoover
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

9.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.

Authors:  M Farlow; S I Gracon; L A Hershey; K W Lewis; C H Sadowsky; J Dolan-Ureno
Journal:  JAMA       Date:  1992-11-11       Impact factor: 56.272

10.  A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

Authors:  M J Knapp; D S Knopman; P R Solomon; W W Pendlebury; C S Davis; S I Gracon
Journal:  JAMA       Date:  1994-04-06       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.